| Ytd | 26.01% | |
| 1y | -7.10% |
| Open | 7.75 | Prev Close | 7.73 | Low | 7.31 | High | 7.95 | Mkt Cap | 460.67M |
| Vol | 1.25M | Avg Vol | 1.80M | EPS | -1.35 | P/E | N/A | Forward P/E | -1.40 |
| Beta | N/A | Short Ratio | 1.37 | Inst. Own | 66.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 7.11 | 200-d Avg | 6.55 | 1yr Est | 29.14 |
SGMT News
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clin
US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.
https://www.gov.uk/government/news/resmetirom-rezdiffra-authorised-to-treat-metabolic-dysfunction-as
Phase 1 clinical data poster selected as a Best of EASL 2026 presentationCombination of denifanstat
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outp
Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.33) per share which beat the anal
Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and
Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lo
Sagimet shares surge as Phase 3 acne trial plans and $175M offering fund pipeline through 2028, with
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to in
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with
Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.29) per share which beat the anal
Guggenheim analyst Seamus Fernandez initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable
Barclays analyst Eliana Merle initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Equa
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel
License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom activ
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acqu
Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbe
Shares of TechTarget, Inc. (NASDAQ: TTGT) rose sharply during Thursday’s session after the company a
On Thursday, 369 companies hit new 52-week lows.
On Wednesday, 311 stocks hit new 52-week lows.
On Monday, 369 companies set new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
Wednesday's session saw 150 companies set new 52-week lows.
On Tuesday, 210 companies reached new 52-week lows.